infexn® is an advanced Next-Generation Sequencing (NGS)-based infectious disease diagnostic platform developed by HaystackAnalytics to help clinicians rapidly identify the cause of infections with greater accuracy than conventional diagnostic methods. Designed for hospitals and diagnostic laboratories, infexn® enables comprehensive detection of bacteria, fungi, major respiratory and neuropathic viruses, and antibiotic resistance genes (ARGs) from a single clinical sample, supporting faster and more informed treatment decisions.

HaystackAnalytics is a precision diagnostics and clinical genomics company that leverages Next-Generation Sequencing (NGS), bioinformatics, and artificial intelligence to transform disease diagnosis and personalized healthcare. The company's portfolio includes genomic solutions for infectious disease detection, antimicrobial resistance profiling, inherited disease testing, and pharmacogenomics. Through its healthcare platforms—including identifi, its consumer genomics offering— HaystackAnalytics aims to make advanced genomic testing more accessible, enabling clinicians and patients to make informed, data-driven healthcare decisions.

HaystackAnalytics is a precision diagnostics and clinical genomics company that leverages Next-Generation Sequencing (NGS), bioinformatics, and artificial intelligence to transform disease diagnosis and personalized healthcare. The company's portfolio includes genomic solutions for infectious disease detection, antimicrobial resistance profiling, inherited disease testing, and pharmacogenomics. Through its healthcare platforms—including identifi, its consumer genomics offering— HaystackAnalytics aims to make advanced genomic testing more accessible, enabling clinicians and patients to make informed, data-driven healthcare decisions.